Sanofi-Aventis S.A. (SNY)
$43.41 0.00 (0.00%)
17:16 EST SNY Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 107.59B
PE Ratio 29.04
Volume (Avg. Vol.)
Day's Range 43.41 - 43.41
52-Week Range -
Dividend & Yield 1.86 (4.29%)
SNY Stock Predictions, Articles, and Sanofi-Aventis S.A. News
- From InvestorPlace
- From the Web
By Alex Sirois
Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.
These 6 cannabis stocks show promise in the medical and recreational ends of the burgeoning marijuana sector, set to grow even more in 2021.
Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021.
Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives. With them, we can solve Covid-19.
GlaxoSmithKline and Sanofi stock are rallying in early trading on Friday thanks to news they would supply the EU 300 million vaccine doses.
SNY stock is no longer a sleepy passive investment. Under a new CEO, Sanofi is less reliant on diabetes and heart drugs and looking to buy pre-market cancer blockbusters.
Biotech stocks are on fire at the moment. That said, here are five names from the sector that offer long-term value and strong fundamentals.
As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday due to poor results for the period.
Despite their indispensable demand, pharmaceutical stocks face tough roadblocks as competition for breakthrough drugs intensifies.
The upside case for pharmaceutical stocks is building. The midterm elections results mean its unlikely drug price regulation will happen soon.
SNY stock beat on earnings and missed on revenue, but sales of newer drugs as well as a low P/E and a high dividend show promise for Sanofi.
Pfizer renewed the drug price hike cycle after it raised them for around 40 products. If other biotech stocks follow, profits will soar.
Put these tickers on a list of stocks to buy here in the midst of market-wide carnage. They're likely to recover first and best once the selloff settles.
Sanofi (SNY) inks second multi-dollar deal this month. Since the earlier deal last Monday, SNY stock gained 2.6% in a week.
Navellier RatingsPowered by Portfolio Grader